Back to News
Market Impact: 0.3
PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
PTC Therapeutics completed its previously announced acquisition of ST-920 from Sangamo Therapeutics. ST-920 is an investigational, BLA-stage AAV gene therapy for Fabry disease, adding a late-stage rare-disease asset to PTC's pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PTCT0.55
SGMOQ0.40
More News
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- Fox completes its $22B acquisition of Roku
- Fox wraps up its $22 billion Roku deal
- Fox completes $22 billion Roku deal to expand digital reach
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Crusoe sells troubled Wyoming data center project to Google